Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
APTO

APTO - Aptose Biosciences Inc Stock Price, Fair Value and News

1.84USD-0.06 (-3.16%)Market Closed
Watchlist

Market Summary

USD1.84-0.06
Market Closed
-3.16%

APTO Stock Price

View Fullscreen

APTO RSI Chart

APTO Valuation

Market Cap

14.4M

Price/Earnings (Trailing)

-0.29

Price/Sales (Trailing)

149.26

Price/Free Cashflow

-0.35

APTO Price/Sales (Trailing)

APTO Profitability

Return on Equity

-633.38%

Return on Assets

-235.93%

Free Cashflow Yield

-288.76%

APTO Fundamentals

APTO Earnings

Earnings (TTM)

-49.3M

Earnings Growth (Yr)

-17.08%

Earnings Growth (Qtr)

18.98%

Breaking Down APTO Revenue

Last 7 days

-3.9%

Last 30 days

-14.5%

Last 90 days

-31.8%

Trailing 12 Months

-81.4%

How does APTO drawdown profile look like?

APTO Financial Health

Current Ratio

1.59

APTO Investor Care

Shares Dilution (1Y)

27.04%

Diluted EPS (TTM)

-7.93

Tracking the Latest Insider Buys and Sells of Aptose Biosciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 22, 2023
seizinger bernd r.
bought
53,380
3.14
17,000
-
Jan 19, 2023
ledru philippe
acquired
-
-
100,000
chief commercial officer
Jan 19, 2023
bejar rafael
acquired
-
-
100,000
sr. vp, chief medical officer
Jan 19, 2023
rice william g.
acquired
-
-
150,000
chair, president & ceo
Jan 19, 2023
payne fletcher
acquired
-
-
100,000
sr vp & chief fin. officer
Sep 19, 2022
rice william g.
bought
6,834
0.6834
10,000
chair, president & ceo
Sep 19, 2022
payne fletcher
bought
6,775
0.6775
10,000
sr vp & chief fin. officer
Jun 06, 2022
rice william g.
bought
9,681
0.9681
10,000
chair, president & ceo
Dec 20, 2021
burger denis r
bought
14,490
1.449
10,000
-
Dec 16, 2021
platzer erich
bought
137,900
1.379
100,000
-

1–10 of 43

Which funds bought or sold APTO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 27, 2024
Beaird Harris Wealth Management, LLC
unchanged
-
-65.00
635
-%
Feb 16, 2024
DRW Securities, LLC
unchanged
-
-154,214
1,505,790
0.02%
Feb 15, 2024
Nantahala Capital Management, LLC
added
76.04
228,118
610,270
0.02%
Feb 14, 2024
Royal Bank of Canada
added
838
15,000
17,000
-%
Feb 14, 2024
CITADEL ADVISORS LLC
added
256
106,718
155,306
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
new
-
39,340
39,340
-%
Feb 14, 2024
Annandale Capital, LLC
unchanged
-
-21,000
188,000
0.04%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
reduced
-92.86
-3,666
254
-%
Feb 14, 2024
GROUP ONE TRADING, L.P.
unchanged
-
-33.00
289
-%
Feb 13, 2024
TORONTO DOMINION BANK
sold off
-100
-12,877
-
-%

1–10 of 32

Are Funds Buying or Selling APTO?

Are funds buying APTO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own APTO
No. of Funds

Unveiling Aptose Biosciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
nantahala capital management, llc
1.5%
120,132
SC 13G/A
Feb 05, 2024
hanmi pharmaceutical co., ltd.
22.17%
2,989,415
SC 13D/A
Sep 12, 2023
hanmi pharmaceutical co., ltd.
12.07%
884,152
SC 13D
Feb 14, 2023
nantahala capital management, llc
6.6%
6,052,867
SC 13G/A
Jan 17, 2023
fletcher aaron g.l.
3.6%
3,311,458
SC 13G
Feb 14, 2022
nantahala capital management, llc
8.5%
7,604,693
SC 13G/A
Feb 11, 2022
orbimed capital llc
0.00%
0
SC 13G/A
Aug 10, 2021
wilson donald r. jr.
993%
8,888,275
SC 13G/A
Feb 17, 2021
consonance capital management lp
-
0
SC 13G/A
Feb 16, 2021
consonance capital management lp
-
0
SC 13G/A

Recent SEC filings of Aptose Biosciences Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 07, 2024
4
Insider Trading
Feb 07, 2024
4
Insider Trading
Feb 07, 2024
4
Insider Trading
Feb 07, 2024
4
Insider Trading
Feb 07, 2024
4
Insider Trading
Feb 07, 2024
4
Insider Trading
Feb 07, 2024
4
Insider Trading
Feb 07, 2024
4
Insider Trading
Feb 07, 2024
4
Insider Trading

Peers (Alternatives to Aptose Biosciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.8B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.5B
1.8B
-23.99% -31.71%
-44.39
10.69
76.23% 61.08%
17.2B
2.4B
-4.89% -18.90%
102.64
7.11
15.42% 18.43%
13.5B
3.7B
-7.62% -26.87%
22.54
3.64
8.87% 75.42%
MID-CAP
8.2B
396.6M
-2.06% 34.31%
-15.49
20.64
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.55
60.35
54.84% -25.61%
4.2B
240.7M
-19.08% -10.99%
-14.19
17.5
-1.03% -92.09%
3.9B
270.6M
8.92% 47.81%
-16.43
14.52
440.80% -27.84%
3.9B
631.9M
-12.60% 32.37%
-26.2
6.17
23.54% 31.53%
SMALL-CAP
1.6B
348.4M
-3.38% -9.50%
25.02
4.46
81.69% -7.29%
521.5M
1.0B
-9.17% -57.89%
-0.95
0.5
-43.15% 58.48%
192.2M
4.9M
-14.18% -58.18%
-1.17
39.32
-57.57% 50.48%
123.2M
881.7K
289.54% 381.25%
-2.6
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Aptose Biosciences Inc News

Latest updates
InvestorsObserver06 Feb 202408:00 am
Yahoo Finance UK05 Feb 202408:00 am
InvestorPlace26 Jan 202408:00 am
InvestorPlace9 months ago
The Motley Fool3 years ago

Aptose Biosciences Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-21.4%21.0027.0039.0051.0057.0065.0073.0083.0097.0010611512613585.0093.0010032.0038.0020.0017.0016.00
  Current Assets-22.1%20.0025.0038.0050.0057.0064.0072.0082.0096.0010511412513484.0091.0099.0031.0036.0018.0016.0016.00
    Cash Equivalents87.1%16.008.0023.0037.0028.0040.0037.0039.0075.0083.0087.0011710054.0060.0080.0021.0027.0017.0015.0015.00
  Net PPE-10.5%0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
Liabilities2.4%13.0013.0013.0013.0010.009.007.008.009.008.006.007.006.006.005.007.005.004.004.003.00-
  Current Liabilities3.4%12.0012.0012.0012.0010.009.007.008.008.008.005.007.005.005.004.006.004.003.003.003.002.00
Shareholder's Equity-43.6%8.0014.0026.0038.0047.0055.0065.0074.0089.0098.0010911912979.0087.0094.0027.0034.0015.0014.0014.00
  Retained Earnings-2.3%-503-492-478-464-454-444-433-422-398-386-373-357-342-329-313-301-294-287-281-275-269
  Additional Paid-In Capital0.8%72.0071.0070.0069.0068.0067.0066.0064.0061.0060.0057.0051.0046.0046.0039.0035.0035.0034.0034.0033.0033.00
Shares Outstanding18.3%8.006.006.006.006.006.006.006.006.006.006.006.006.00--------
Float------68.00---293---478---143---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations22.0%-10,536-13,503-11,302-8,651-6,979-7,047-9,645-16,044-8,059-8,825-10,376-10,348-8,270-7,164-8,111-6,231-5,184-5,269-4,874-5,502-4,468
  Share Based Compensation-22.1%5997691,8748611,0537792,5142,3141,8282,1646,6434,4314,9057,7014,401562504568662581952
Cashflow From Investing760.9%12,953-1,960-2,96017,573-5,07810,0667,505-20,010-1854,999-20,01227,967-4,3981,479-12,427-8,278-1,042-8,026-24.00-86.00-28.00
Cashflow From Financing344.0%4,9021,10450.0051.0021.0029.0015.0066.00-85.0075.0042.0058,28346.0043673,64017.0023,6136,1785,8391,608

APTO Income Statement

2023-09-30
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue$ 0$ 0$ 0$ 0
Expenses:    
Research and development8,2566,57827,64921,312
General and administrative3,4253,44812,58010,887
Operating expenses11,68110,02640,22932,199
Other income/(expense):    
Interest income232254980387
Foreign exchange gain/(loss)2(5)(3)(11)
Total other income234249977376
Net loss(11,447)(9,777)(39,252)(31,823)
Other comprehensive loss:    
Unrealized gain (loss) on available-for-sale securities0203(17)
Total comprehensive loss$ (11,447)$ (9,757)$ (39,249)$ (31,840)
Basic loss per common share (in dollars per share)$ (1.76)$ (1.59)$ (6.14)$ (5.17)
Diluted loss per common share (in dollars per share)$ (1.76)$ (1.59)$ (6.14)$ (5.17)
Weighted average number of common shares outstanding (in thousands) used in the calculation of basic loss per common share (in shares)6,4956,1536,3916,150
Weighted average number of common shares outstanding used in the calculation of diluted loss per common share ( in shares)6,4956,1536,3916,150

APTO Balance Sheet

2023-09-30
Condensed Consolidated Interim Statements of Financial Position (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 15,720$ 36,970
Investments1,9979,989
Prepaid expenses1,6932,303
Other current assets261257
Total current assets19,67149,519
Non-current assets:  
Property and equipment170211
Right-of-use assets, operating leases1,0351,297
Total non-current assets1,2051,508
Total assets20,87651,027
Current liabilities:  
Accounts payable2,8116,326
Accrued liabilities9,1295,657
Advance for Equity Issuance Current50 
Current portion of lease liability, operating leases390301
Total current liabilities12,38012,284
Non-current liabilities:  
Lease liability, operating leases7201,002
Total liabilities13,10013,286
Shareholders' equity:  
Common shares, no par value, unlimited authorized shares, 7,542,760 and 6,157,749 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively443,938437,520
Additional paid-in capital71,73568,869
Accumulated other comprehensive loss(4,315)(4,318)
Deficit(503,582)(464,330)
Total shareholders’ equity7,77637,741
Total liabilities and shareholders’ equity$ 20,876$ 51,027
APTO
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
 CEO
 WEBSITEwww.aptose.com
 EMPLOYEES35

Aptose Biosciences Inc Frequently Asked Questions


What is the ticker symbol for Aptose Biosciences Inc? What does APTO stand for in stocks?

APTO is the stock ticker symbol of Aptose Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aptose Biosciences Inc (APTO)?

As of Tue Feb 27 2024, market cap of Aptose Biosciences Inc is 14.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APTO stock?

You can check APTO's fair value in chart for subscribers.

What is the fair value of APTO stock?

You can check APTO's fair value in chart for subscribers. The fair value of Aptose Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aptose Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APTO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aptose Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether APTO is over valued or under valued. Whether Aptose Biosciences Inc is cheap or expensive depends on the assumptions which impact Aptose Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APTO.

What is Aptose Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 27 2024, APTO's PE ratio (Price to Earnings) is -0.3 and Price to Sales (PS) ratio is 149.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APTO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Aptose Biosciences Inc's stock?

In the past 10 years, Aptose Biosciences Inc has provided -0.339 (multiply by 100 for percentage) rate of return.